Proteotype Diagnostics

Proteotype Diagnostics is a private, pre-revenue diagnostics company developing a proprietary proteomic liquid biopsy platform named Enlighten. The technology analyzes the host proteomic response to predict disease development and treatment outcomes before and during therapy, positioning it in the predictive and monitoring diagnostics space. Based in Cambridge, UK, the company is currently for performance evaluation only and is backed by undisclosed investors. Its core value proposition is enabling more precise, personalized treatment decisions across oncology and likely other therapeutic areas.

The 'Enlighten' platform uses liquid biopsy to profile a patient's dynamic proteotype (host protein response) as a leading indicator of disease. It aims to predict treatment response prior to therapy and monitor for resistance during treatment via minimally invasive blood sampling.

The competitive landscape is crowded with large diagnostic firms and startups in liquid biopsy (e.g., Guardant, Freenome) and proteomics (e.g., SomaLogic, Olink). Proteotype's differentiation lies in its specific focus on the pre-treatment predictive proteotype, but it faces rivals with more advanced clinical data and substantial financial resources.